Rozanolixizumab fails to show broad efficacy in severe fibromyalgia trial.
Rozanolixizumab fails to show broad efficacy in severe fibromyalgia trial
Rozanolixizumab fails to show broad efficacy in severe fibromyalgia trial. Rozanolixizumab did not demonstrate broad efficacy in this severe fibromyalgia population. Randomised trial, Lancet Rheumatology, 16 Sep 2026.
enclai.net
September 29, 2026 at 6:00 AM
Rozanolixizumab fails to show broad efficacy in severe fibromyalgia trial.
Rozanolixizumab now sits beside efgartigimod and immunoglobulin in myasthenia gravis, but anchored and unanchored adjustments differ in weight. https://www.mattheneus.com/editorial/pubmed-rozanolixizumab-fcrn-anchored-unanchored-population-adjustment-evidence-2026-09-29 #HTA #MAIC #EvidenceSynthesis
September 29, 2026 at 12:02 PM
Rozanolixizumab now sits beside efgartigimod and immunoglobulin in myasthenia gravis, but anchored and unanchored adjustments differ in weight. https://www.mattheneus.com/editorial/pubmed-rozanolixizumab-fcrn-anchored-unanchored-population-adjustment-evidence-2026-09-29 #HTA #MAIC #EvidenceSynthesis
1) There was a randomized, crossover trial of the monoclonal antibody Rozanolixizumab for severe fibromyalgia.
The trial explored a possible autoimmune hypothesis of FM. It looks like the initiative came from the company UCB Biopharma, the producer of the drug.
The trial explored a possible autoimmune hypothesis of FM. It looks like the initiative came from the company UCB Biopharma, the producer of the drug.
July 5, 2025 at 9:42 AM
1) There was a randomized, crossover trial of the monoclonal antibody Rozanolixizumab for severe fibromyalgia.
The trial explored a possible autoimmune hypothesis of FM. It looks like the initiative came from the company UCB Biopharma, the producer of the drug.
The trial explored a possible autoimmune hypothesis of FM. It looks like the initiative came from the company UCB Biopharma, the producer of the drug.
10) Link to the paper:
Goebel et al. 2026. Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.
www.thelancet.com/jo...
Goebel et al. 2026. Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.
www.thelancet.com/jo...
September 20, 2026 at 7:29 AM
10) Link to the paper:
Goebel et al. 2026. Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.
www.thelancet.com/jo...
Goebel et al. 2026. Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.
www.thelancet.com/jo...
9) Another issue for the trial is that the authors could not identify fibromyalgia patients in whom antibodies are pathological. There's no validated test for this yet. This lack of a target group makes it more difficult to evaluate treatments such as Rozanolixizumab.
September 20, 2026 at 7:29 AM
9) Another issue for the trial is that the authors could not identify fibromyalgia patients in whom antibodies are pathological. There's no validated test for this yet. This lack of a target group makes it more difficult to evaluate treatments such as Rozanolixizumab.
8) There's also a conflict of interest as Goebel received consultancy fees from UCB, the company developing rozanolixizumab, and he is a co-inventor on a patent application concerning the use of neonatal Fc receptor antagonists to treat fibromyalgia.
September 20, 2026 at 7:29 AM
8) There's also a conflict of interest as Goebel received consultancy fees from UCB, the company developing rozanolixizumab, and he is a co-inventor on a patent application concerning the use of neonatal Fc receptor antagonists to treat fibromyalgia.
3) In this study the authors tested Rozanolixizumab in 63 patients with severe fibromyalgia (pain score of 6 out of 10 or greater).
Antibody levels dropped by approximately 37% in the treatment groups.
Antibody levels dropped by approximately 37% in the treatment groups.
September 20, 2026 at 7:28 AM
3) In this study the authors tested Rozanolixizumab in 63 patients with severe fibromyalgia (pain score of 6 out of 10 or greater).
Antibody levels dropped by approximately 37% in the treatment groups.
Antibody levels dropped by approximately 37% in the treatment groups.
2) Rozanolixizumab is a monoclonal antibody that targets the neonatal Fc receptor (FcRn). This receptor normally protects antibodies from breakdown, so blocking it leads to a reduction in antibodies.
The drug is already approved as a treatment for myasthenia gravis.
The drug is already approved as a treatment for myasthenia gravis.
September 20, 2026 at 7:28 AM
2) Rozanolixizumab is a monoclonal antibody that targets the neonatal Fc receptor (FcRn). This receptor normally protects antibodies from breakdown, so blocking it leads to a reduction in antibodies.
The drug is already approved as a treatment for myasthenia gravis.
The drug is already approved as a treatment for myasthenia gravis.
4) Rozanolixizumab is used as a treatment for the autoimmune disease myasthenia gravis. It blocks the Fc receptor which normally helps extend the lifespan of antibodies by preventing them from being broken down.
July 5, 2025 at 9:42 AM
4) Rozanolixizumab is used as a treatment for the autoimmune disease myasthenia gravis. It blocks the Fc receptor which normally helps extend the lifespan of antibodies by preventing them from being broken down.
Nipocalimab (Johnson and Johnson) or Rozanolixizumab (UCB Pharma) have very similar mechanisms and might be options.
January 30, 2025 at 9:31 PM
Nipocalimab (Johnson and Johnson) or Rozanolixizumab (UCB Pharma) have very similar mechanisms and might be options.
Want to hear the results of a randomized placebo-controlled Phase IIa trial investigating rozanolixizumab, an FcRn inhibitor, in patients with CIDP?
Then check out our interview with Luis Querol Gutierrez here:
🎥 https://buff.ly/4fJyPEs
#CTSM #TrialUpdate #EAN2024 #Neuroscience
Then check out our interview with Luis Querol Gutierrez here:
🎥 https://buff.ly/4fJyPEs
#CTSM #TrialUpdate #EAN2024 #Neuroscience
December 4, 2024 at 9:00 AM
Want to hear the results of a randomized placebo-controlled Phase IIa trial investigating rozanolixizumab, an FcRn inhibitor, in patients with CIDP?
Then check out our interview with Luis Querol Gutierrez here:
🎥 https://buff.ly/4fJyPEs
#CTSM #TrialUpdate #EAN2024 #Neuroscience
Then check out our interview with Luis Querol Gutierrez here:
🎥 https://buff.ly/4fJyPEs
#CTSM #TrialUpdate #EAN2024 #Neuroscience
What is the safety and efficacy of cyclic #rozanolixizumab in generalised #MyastheniaGravis?
Results from the final pooled analysis of the phase III MycarinG study and two open-label extensions: journals.sagepub.com/doi/full/10....
Results from the final pooled analysis of the phase III MycarinG study and two open-label extensions: journals.sagepub.com/doi/full/10....
August 14, 2026 at 11:13 AM
What is the safety and efficacy of cyclic #rozanolixizumab in generalised #MyastheniaGravis?
Results from the final pooled analysis of the phase III MycarinG study and two open-label extensions: journals.sagepub.com/doi/full/10....
Results from the final pooled analysis of the phase III MycarinG study and two open-label extensions: journals.sagepub.com/doi/full/10....
New online!
What is the efficacy and safety of cyclic #rozanolixizumab in generalized #MyastheniaGravis?
Our condolences to the family, friends and colleagues to Dr Vera Bril, the first author of this article, who passed away shortly after its publication.
journals.sagepub.com/doi/full/10....
What is the efficacy and safety of cyclic #rozanolixizumab in generalized #MyastheniaGravis?
Our condolences to the family, friends and colleagues to Dr Vera Bril, the first author of this article, who passed away shortly after its publication.
journals.sagepub.com/doi/full/10....
July 23, 2026 at 3:27 PM
New online!
What is the efficacy and safety of cyclic #rozanolixizumab in generalized #MyastheniaGravis?
Our condolences to the family, friends and colleagues to Dr Vera Bril, the first author of this article, who passed away shortly after its publication.
journals.sagepub.com/doi/full/10....
What is the efficacy and safety of cyclic #rozanolixizumab in generalized #MyastheniaGravis?
Our condolences to the family, friends and colleagues to Dr Vera Bril, the first author of this article, who passed away shortly after its publication.
journals.sagepub.com/doi/full/10....
Rozanolixizumab zeigte in dieser Studie keine Wirksamkeit bei Patienten mit CIDP. R wurde auch langfristig bei wöchentlicher Anwendung gut vertragen, mit einem akzeptablen Sicherheitsprofil.
Hier der Link zur englischen Veröffentlichung:
jnnp.bmj.com/content/95/9...
@unidue.bsky.social
3/3
Hier der Link zur englischen Veröffentlichung:
jnnp.bmj.com/content/95/9...
@unidue.bsky.social
3/3
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, ph...
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nerve disorder characterised by weakness and sensory loss. We assessed the neonatal Fc receptor inhibitor ro...
jnnp.bmj.com
March 10, 2025 at 5:54 PM
Rozanolixizumab zeigte in dieser Studie keine Wirksamkeit bei Patienten mit CIDP. R wurde auch langfristig bei wöchentlicher Anwendung gut vertragen, mit einem akzeptablen Sicherheitsprofil.
Hier der Link zur englischen Veröffentlichung:
jnnp.bmj.com/content/95/9...
@unidue.bsky.social
3/3
Hier der Link zur englischen Veröffentlichung:
jnnp.bmj.com/content/95/9...
@unidue.bsky.social
3/3
#generalisedmyastheniagravis #gMG #UCB #Rystiggo #rozanolixizumab #NICE #NHS #HEOR #Neuromusculardiseases #uncontrolledgMGtherapy #rarediseases #NICEguidance #reimbursement #NICEcosteffectivenessmodelling #NICEdecisionmaking #InnovativeMedicinesFund #IMF #gMGcommunitypatients
zurl.co/Tj9mI
zurl.co/Tj9mI
NICE backs UCB drug as first uncontrolled gMG therapy
UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.
pharmaphorum.com
May 6, 2026 at 9:38 AM
NEW RESEARCH—Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial www.thelancet.com/journals/lan... #MedSky #RheumSky
September 17, 2026 at 10:16 AM
NEW RESEARCH—Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial www.thelancet.com/journals/lan... #MedSky #RheumSky
How long does Rystiggo take to work? It may start within one week of the first dose. In a clinical trial, people with generalized myasthenia gravis saw improvements in daily activities by six weeks. Individual responses vary, so track progress with your provider.
How long does it take Rystiggo to work?
Official answer: Rystiggo (rozanolixizumab) may start working within one week of the first dose. In a clinical trial, patients saw...
www.drugs.com
July 23, 2026 at 7:00 AM
How long does Rystiggo take to work? It may start within one week of the first dose. In a clinical trial, people with generalized myasthenia gravis saw improvements in daily activities by six weeks. Individual responses vary, so track progress with your provider.
Chronisch inflammatorische demyelinisierende Polyradikuloneuropathie (CIDP) ist eine Erkrankung der peripheren Nerven, die durch Schwäche und sensorische Ausfälle gekennzeichnet ist. Diese Studie untersuchten den neonatalen Fc-Rezeptor-Inhibitor Rozanolixizumab zur Behandlung von CIDP.
1/3
1/3
March 10, 2025 at 5:54 PM
Chronisch inflammatorische demyelinisierende Polyradikuloneuropathie (CIDP) ist eine Erkrankung der peripheren Nerven, die durch Schwäche und sensorische Ausfälle gekennzeichnet ist. Diese Studie untersuchten den neonatalen Fc-Rezeptor-Inhibitor Rozanolixizumab zur Behandlung von CIDP.
1/3
1/3
Wirksamkeit, Sicherheit und Verträglichkeit von Rozanolixizumab bei Patienten mit chronisch entzündlicher demyelinisierender Polyradikuloneuropathie: eine randomisierte, teilnehmerverblindete, prüferverblindete, placebokontrollierte Phase-2a-Studie und eine offene Verlängerungsstudie.
1/3
1/3
March 10, 2025 at 5:54 PM
Wirksamkeit, Sicherheit und Verträglichkeit von Rozanolixizumab bei Patienten mit chronisch entzündlicher demyelinisierender Polyradikuloneuropathie: eine randomisierte, teilnehmerverblindete, prüferverblindete, placebokontrollierte Phase-2a-Studie und eine offene Verlängerungsstudie.
1/3
1/3
NEW research paper in JND = open label extension study of the neonatal Fc receptor inhibitor Rozanolixizumab #MyastheniaGravis:
- Clinically meaningful and consistent improvement
- Acceptable safety profile
- Beneficial in AChR and MuSK MG
Read the report here journals.sagepub.com/doi/full/10....
- Clinically meaningful and consistent improvement
- Acceptable safety profile
- Beneficial in AChR and MuSK MG
Read the report here journals.sagepub.com/doi/full/10....
April 30, 2025 at 7:49 AM
NEW research paper in JND = open label extension study of the neonatal Fc receptor inhibitor Rozanolixizumab #MyastheniaGravis:
- Clinically meaningful and consistent improvement
- Acceptable safety profile
- Beneficial in AChR and MuSK MG
Read the report here journals.sagepub.com/doi/full/10....
- Clinically meaningful and consistent improvement
- Acceptable safety profile
- Beneficial in AChR and MuSK MG
Read the report here journals.sagepub.com/doi/full/10....
rozanolixizumab
zilucoplan
efgartigimod alfa
That's effed up, gartigimod alfa.
Rosanna Rosanna Dannolixizumab
zilucoplan
efgartigimod alfa
That's effed up, gartigimod alfa.
Rosanna Rosanna Dannolixizumab
March 6, 2025 at 4:54 PM
rozanolixizumab
zilucoplan
efgartigimod alfa
That's effed up, gartigimod alfa.
Rosanna Rosanna Dannolixizumab
zilucoplan
efgartigimod alfa
That's effed up, gartigimod alfa.
Rosanna Rosanna Dannolixizumab
Rozanolixizumab'ın riskli gebeliklerde konjenital kalp bloğunu önlediği kanıtlanmış.
Drug Prevents Congenital Heart Block Recurrence in a High-Risk Pregnancy
An NYU Langone study shows the feasibility and safety of using rozanolixizumab to prevent congenital heart block on the offspring of women with lupus.
nyulangone.org
October 23, 2025 at 2:40 PM
Rozanolixizumab'ın riskli gebeliklerde konjenital kalp bloğunu önlediği kanıtlanmış.